Pfizer, Merck KGaA roll into Phase III with cancer immunotherapy; Allergan cutting 577 more jobs;

@FierceBiotech: Roche bets $555M on an Indian biotech's immuno-oncology drug. News | Follow @FierceBiotech

@JohnCFierce: What's driving the massive social media campaign for Genervon's ALS drug? (Exaggerated claims and a false assumption). Editor's corner | Follow @JohnCFierce

@DamianFierce: "No immediate response from the company, which ... has cited biblical prophecy as an inspiration for its work." Article | Follow @DamianFierce

> Partners Pfizer ($PFE) and Merck KGaA have kicked off Phase III development for avelumab, a checkpoint-blocking immunotherapy, planning to enroll patients with non-small cell lung cancer in the first of many late-stage trials. More

> Merck ($MRK) is working with TetraLogic on a trial combining its PD-1 inhibitor Keytruda with the latter company's immune-modulating birinapant on patients with solid tumors. News

> Allergan is canning 577 workers as part of new parent Actavis' ($ACT) plan to cut costs. Story

Medical Device News

@FierceMedDev: ICYMI: NEA-backed Cartiva raises $6M after a recent FDA nod, as it heads into a PMA review. Story | Follow @FierceMedDev

@VarunSaxena2: UPDATED: HeartWare device meets trial endpoint, but stroke data a big concern. ICYMI | Follow @VarunSaxena2

@EmilyWFierce: VisualDx sees big future for mobile diagnostic tool. FierceDiagnostics report | Follow @EmilyWFierce

> FDA approves first near vision correcting implant that doesn't require cataract surgery. More

> Endo settles more than 350 vaginal mesh suits. Article

> Report: Patterson Companies looking to shed rehab supply business. Story

Pharma News

@FiercePharma: Shanghai Haohai Biological plans Hong Kong IPO to raise $263M. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: 275 GSK jobs at risk with consumer health move from Pittsburgh. Some will get offers in New Jersey. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bad news, Teva--Sandoz has an FDA nod for generic Copaxone. But when will it launch? Story | Follow @CarlyHFierce

> Pfizer prevails in first court test of Zoloft birth-defect claims. Report

> Allergan to cut loose 577 more workers in Irvine. News

> Which deal gets done: Teva's rumored Mylan bid or Mylan's Perrigo offer? More

Animal Health News

> Fears of dog flu epidemic spread as questions arise about vaccine's effectiveness. News

> UN restrictions on narcotic ketamine would impede veterinary practices, trade group argues. More

> FDA coordinates with pharma to address IV fluid shortage. Item

> Cannabis biscuits sell out as lobbyists push medical marijuana rights for pets. Story

> Nexvet regroups as key study on lead dog drug shows 'low probability' of success. Article

Biotech IT News

> Sanofi sues drug information startup over side effect info. Item

> Biopharma puts better use of existing data at top of R&D wish list. More

> Apple, IBM team up for Watson-fueled assault on health research. Article

> California starts statewide precision medicine initiative with Atul Butte at the helm. Story

> PatientsLikeMe adds AstraZeneca to growing list of big-name clients. Report

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.